VIDEO: Combination of BTK inhibitor with venetoclax shows promise in mantle cell lymphoma
Click Here to Manage Email Alerts
In this video, Stephen M. Ansell, MD, PhD, discusses primary analysis results from the phase 3 Sympatico study.
The results, presented at ASH Annual Meeting and Exposition, showed a benefit in combining a BTK and BCL-2 inhibitor for relapsed/refractory mantle cell lymphoma, Ansell, professor of medicine in the department of hematology at Mayo Clinic, Minnesota, said.
The addition of venetoclax (Venclexta; AbbVie, Genentech) to ibrutinib (Imbruvica; Janssen, Pharmacyclics) showed benefit over ibrutinib and placebo alone, Ansell said.
"That's a study with pretty substantial follow-up showing benefit. In that Sympatico study, there was the use of both agents together for a 2-year period, and then just the BTK inhibitor thereafter — but that was clearly better than just using a BTK inhibitor," Ansell said.
Reference:
- Wang M, et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: Primary analysis results from the randomized phase 3 Sympatico study. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts